Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6
|
| pubmed:dateCreated |
1996-11-26
|
| pubmed:abstractText |
In a prospective multicenter phase-II trial 80 patients with Philadelphia (Ph)-positive chronic myelogenous leukemia (CML) were treated with recombinant interferon (IFN) alpha-2c, administered subcutaneously at an absolute dose of 3.5 megaunits (MU)/day. Complete hematological remission was achieved in 29 (39%) and partial hematological remission in 26 (35%) of the 74 patients evaluable for response. Major cytogenetic responses were observed in ten (13%) and minor cytogenetic responses in 11 patients (15%). Median duration of cytogenetic response was 33 months (range, 2-90); relapses were seen in all of the 11 patients with minor and in three of the ten patients with major cytogenetic responses. Median survival estimates for pretreated (n = 19) and untreated (n = 58) patients were 51 months (95% confidence interval [CI], 30-72) and 77 months (95% CI, 43-111), and the survival probabilities at 5 years were 45% and 54% for the two groups, respectively. Hematological response after 3 months of treatment demonstrated a clear-cut discriminative capacity with 5-year survival probabilities of 100%, 67% and 24% for patients achieving CHR (n = 6), PHR (n = 34), and less than PHR (n = 35), respectively. Landmark analysis at 12, 18, and 24 months after start of IFN therapy and an analysis treating time to cytogenetic response as a time-dependent covariate showed that cytogenetic response was associated with longer survival. The impact of a low-dose IFN regimen on survival in CML patients is unclear and requires further clarification by randomized clinical trials. Early hematological and cytogenetic response to IFN-alpha treatment identifies patients with a favorable long-term prognosis.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
0939-5555
|
| pubmed:author |
pubmed-author:AulitzkyWW,
pubmed-author:DubaCC,
pubmed-author:FalkMM,
pubmed-author:FluckingerTT,
pubmed-author:GastlGG,
pubmed-author:HuberCC,
pubmed-author:HuberHH,
pubmed-author:KührTT,
pubmed-author:LangAA,
pubmed-author:NiederwieserDD,
pubmed-author:SeewannHH,
pubmed-author:SillHH,
pubmed-author:ThalerJJ,
pubmed-author:UtermannGG
|
| pubmed:issnType |
Print
|
| pubmed:volume |
72
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
349-55
|
| pubmed:dateRevised |
2011-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:8767103-Adolescent,
pubmed-meshheading:8767103-Adult,
pubmed-meshheading:8767103-Aged,
pubmed-meshheading:8767103-Antineoplastic Agents,
pubmed-meshheading:8767103-Child,
pubmed-meshheading:8767103-Cytogenetics,
pubmed-meshheading:8767103-Female,
pubmed-meshheading:8767103-Humans,
pubmed-meshheading:8767103-Interferon Type I,
pubmed-meshheading:8767103-Leukemia, Myelogenous, Chronic, BCR-ABL Positive,
pubmed-meshheading:8767103-Longitudinal Studies,
pubmed-meshheading:8767103-Lymphocyte Activation,
pubmed-meshheading:8767103-Male,
pubmed-meshheading:8767103-Middle Aged,
pubmed-meshheading:8767103-Prospective Studies,
pubmed-meshheading:8767103-Recombinant Proteins,
pubmed-meshheading:8767103-Remission Induction,
pubmed-meshheading:8767103-Risk Factors,
pubmed-meshheading:8767103-Survival Analysis
|
| pubmed:year |
1996
|
| pubmed:articleTitle |
Interferon alpha-2c therapy of patients with chronic myelogenous leukemia: long-term results of a multicenter phase-II study. Austrian Biological Response Modifier (BRM) Study Group.
|
| pubmed:affiliation |
Department of Internal Medicine, University Hospital, Innsbruck, Austria.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|